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Mitotic kinesin-like protein 2 (MKlp2), a microtubule-as-
sociatedmotor, is requiredduringmitosis exit for the final
step of cytokinesis. It also contributes to retrograde vesic-
ular trafficking from the Golgi apparatus to the endoplas-
mic reticulum in interphase. The KIF20A gene encoding
MKlp2 is controlled by the E2F–retinoblastoma protein–
p16 pathway, and its widely expressed mRNA is found in
fetal and proliferating adult tissues. The expression pat-
tern and function of MKlp2 in the adult liver, however,
have not been investigated. We report herein that MKlp2
transiently accumulates in vivo during mouse liver regen-
eration after partial hepatectomy and is strongly overex-
pressed in preneoplastic and neoplastic mouse liver. In
vitro in mitogen-stimulated primary hepatocytes, MKlp2
accumulated in thenucleus during theG2phase of the cell
cycle coincident with themitotic kinase Aurora B. Human
hepatoma cell lines exhibited high levels of MKlp2; how-
ever, it was undetectable in normal human hepatocytes.
RNAi-mediated MKlp2 knockdown in hepatoma cells in-
duced polyploidization consistent with its essential func-
tion in promoting cytokinesis and inhibited cell prolifer-
ation without inducing apoptosis. KIF20A mRNA was
strongly accumulated in a large series of human hepato-
cellular carcinomas,with thehighest expressionobserved
in tumors with genomic instability. Accumulation of
MKlp2 in normal proliferating, preneoplastic, and trans-
formed hepatocytes suggests that MKlp2 contributes to
both normal and pathologic hepatocyte prolifera-
tion and is linked to tumor aggressiveness in hu-
man hepatocellular carcinomas. (Am J Pathol 2012,
180:131–140; DOI: 10.1016/j.ajpath.2011.09.040)
Microtubule-associated motor proteins have important
roles in numerous cellular processes including intracel-
lular traffic and cell division. In Saccharomyces cerevisiae,
five kinesins are essential for formation, orientation, and
elongation of the mitotic spindle and for segregation of
chromosomes, whereas in human cells, at least 12 kine-
sins participate in regulating mitosis and cytokinesis.1
Among these, the mitotic kinesin-like proteins MKlp1 and
MKlp2, two closely related members of the kinesin-6 fam-
ily, are required for cytokinesis.2 MKlp1 interacts with
several essential regulators of cytokinesis such as the
complex of passenger proteins, the regulators of RhoA
ECT2 and MgcRacGAP (CYK-4), and Polo-like kinase 1
(Plk-1), and moves them from kinetochores in metaphase
to the central spindle in anaphase, where they remain
until cytokinesis. MKlp2 cooperates with MKlp1 by re-
cruiting and restricting the activities of Plk1 and Aurora B
kinases and of CDC14A phosphatase to the central spin-
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dle during anaphase.3–5 MKlp2 is required for cell ab-
scission, the final step in cytokinesis.1,5–7 During inter-
phase, MKlp2 participates in retrograde vesicular traffic
between the Golgi apparatus and the endoplasmic retic-
ulum.8 This interphasic activity is linked to the ability of
MKlp2 to interact with GTP-bound forms of Rab6; hence
it is also named rabkinesin-6. Levels and activity of
MKlp2 could, therefore, participate in regulation of either
or both intracellular transport and cytokinesis. Little is
known about the regulation of MKlp2 expression. The
mRNA is widely expressed in human fetal tissues and is
particularly abundant in fetal liver and thymus. It is also
expressed in the adult during lymphopoiesis and hema-
topoiesis and in several proliferating tissues such as thy-
mus and testis.9 However, no expression of MKlp2 is
detectable in the adult quiescent human liver.
Under physiologic conditions, the liver is quiescent. In the
adult, hepatocytes are either mononucleate or binucleate and
exhibit various levels of ploidy. However, hepatocytes retain
the unique property to self-renew and to repair the liver ad
integrum when stimulated to proliferate after liver injury. After
partial hepatectomy or liver damage, hepatocytes enter the
cell cycle and proliferate to restore liver mass and function.10
Precise control of hepatocyte proliferation is critical for sup-
pression of tumorigenesis in the liver, and, in turn, liver tumor-
igenesis is favored after chronic liver damage, stimulating cy-
cles of liver regeneration. Deregulation of cell cycle genes,
disruption of the retinoblastoma protein (pRb) pathway, and
loss of expression of the liver-enriched transcription factor
HNF4 are frequent features of liver tumors, which are often
accompanied by nuclear enlargement and increased or ab-
errant ploidy.11–16 MKlp2 as a potential target of both the pRb
pathway6and the HNF4 pathway17 involved in cytokinesis
could be an attractive target for anticancer therapy.
In the present study, we demonstrate that MKlp2 is
overexpressed during normal, preneoplastic, and neo-
plastic hepatocyte proliferation, which suggests that
MKlp2 contributes to both normal and pathologic hepa-
tocyte proliferation. Inhibition of MKlp2 expression by
RNA interference induces polyploidization of human hep-
atoma cells and inhibits cell proliferation without inducing
apoptosis. In addition, in a large series of human hepa-
tocarcinomas, we observed a dramatic increase in
KIF20A mRNA levels linked to genomic instability.
Materials and Methods
Animal Models
For partial hepatectomy, 3- to 4-month-old 129/Sv male
mice were purchased from Charles River Laboratories
France SAS (L’Arbresle, France). Mice were anesthetized
via intraperitoneal injection of xylazine (4.8 mg/kg body
weight; Bayer Schering Pharma AG, Berlin, Germany) and
ketamine (72 mg/kg body weight; Merial SAS, Lyon,
France), and underwent resection of two-thirds of the liver.
After surgery, animals were maintained under standard
conditions. Transgenic ASVmice (C57BL/6J-DBA2) harbor-
ing the SV40 large T antigen on the Y chromosome under
the control of the human antithrombin III regulatory se-
quences have been described previously.18,19 In this
model, all male animals develop hepatocellular carcinoma
(HCC). Nontransgenic male mice were used as controls. An-
imal experiments were conducted in accordancewith national
ethical guidelines for the care and use of laboratory animals.
Isolation of Primary Mouse Hepatocytes
Primary hepatocytes were isolated from 4-week-old
C57B6J mice via liver perfusion using a collagenase
blend (Liberase; Roche Applied Science, Meylan,
France) and then were placed in the mitogenic stimula-
tion medium as previously described.20 Cells were pro-
cessed for immunofluorescence or were scrapped and
frozen for protein analysis.
Ki-67 Immunolabeling on Mouse Liver Sections
After partial hepatectomy, the percentage of hepatocyte
proliferation was evaluated using Ki-67 immunolabeling of
liver sections using a SuperSensitive Link-Label Immuno-
histochemistry Detection System (BioGenex Laboratories,
Inc., San Ramon, CA) according to the manufacturer’s pro-
tocol using anti–Ki-67 antibody (1:100; Novocastra Labora-
tories, Ltd., Newcastle-upon-Tyne, England). A microscope
eyepiece with a net micrometer (Carl Zeiss AG, Jena, Ger-
many) at high magnification (400) was used to count
Ki-67–positive hepatocyte nuclei in 10 consecutive fields
from each liver section (0.96 mm2). Six to eight animals
were analyzed at each time point. Tumoral livers from ASV
mice were treated the same way.
Human Hepatoma Cell Lines and Primary
Hepatocytes
Human hepatoma cell lines (HuH6, HuH7, PLC/PRF/5,
HepG2, and Hep3B) were maintained in minimal essen-
tial medium containing Earle’s salts, 1% nonessential
amino acids, 1 mmol/L sodium pyruvate, and 10% fetal
calf serum. Human primary hepatocytes were prepared
as reported elsewhere.21
RNA Interference
Double-stranded short hairpin RNA (shRNA) correspond-
ing to the cDNA sequence of human KIF20A (5=-AAGAT-
CAGGGTTGTGTCCGTAT-3=) was from 251 to 273 rela-
tive to the first nucleotide of the coding sequence. No
cross-reactive sequence other than the gene of interest
was observed after blast analysis against the human
genome. DNA oligonucleotides were purchased from Eu-
rogentec SA (Seraing, Belgium), annealed, and sub-
cloned in the pSuper vector as described.22 A pSuper
containing a scrambled sequence inefficient in cells
served as control. Cells were electroporated and col-
lected after 36 hours for Western blot analysis and flow
cytometric determination of DNA content as previously
described.23 To quantify the percentages of cells with 2n,
4n, and 4n DNA contents, modeling of the cell cycle
profiles was performed using Multicycle software (Phoe-
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nix Flow Systems, Inc., San Diego, CA) in the two-cycle
mode. The data were interpreted as percentages of cells in
a diploid or tetraploid cycle. Apoptosis was detected 36
hours after transfection with annexin V–FITC and propidium
iodide as recommended by the manufacturer (Apoptosis
Detection Kit; Sigma-Aldrich Corp., St. Louis, MO). For the
colony-formation assay, HuH6 cells were plated at 105 cells
per 25-cm2 flask at 24 hours after co-transfection with the
pSuper vector expressing either MKlp2 or control shRNA
and a neo expressing vector. Cells stably expressing
shRNA were selected for 14 days in the presence of 0.5
mg/mL G418. Cells and colonies were imaged and ana-
lyzed using Adobe Photoshop after fixing with 100% meth-
anol and staining with May-Grünwald-Giemsa.
MKlp2 Expression in Human HCCs
Tumoral and nontumoral adjacent liver tissue specimens
were collected from five patients with HCC who under-
went partial hepatectomy without previous antitumor
treatment. Histologic analyses of nontumoral adjacent
liver tissues demonstrated no fibrosis in three patients
(patients 1, 3, and 4) and cirrhosis in two (patients 2 and
5). Chronic liver disease was related to hepatitis C virus
infection in two patients (patients 2 and 5). All liver tissue
samples were stored at 80°C until analysis. Portions of
the same livers were used for protein extraction, Western
blot analysis, and immunohistochemistry.
Quantitative RT-PCR Analysis of KIF20A mRNA
in Human HCCs
All of the 125 HCCs and 21 nontumor samples have been
previously described by Boyault et al,24 in accordance
with French law and institutional ethical guidelines. In
brief, tissues were immediately snap-frozen in liquid ni-
trogen and stored at 80°C from resected or explanted
HCCs from patients who underwent treatment in France
from 1991 to 2001. The primary clinical and pathologic
features are given in Table 1. Mutations in the TP53 gene
and fractional allelic loss were analyzed as previously
described.24 RNA extraction and quantitative RT-PCR
were performed as previously described.24 In brief, 1 g
total RNA was reverse transcribed using the High Capac-
ity Archive Kit and random hexamers (Applied Biosys-
tems, Inc., Foster City, CA), and 5 L cDNA correspond-
ing to 10 ng reverse-transcribed RNA were analyzed
using TaqMan PCR analysis, in duplicate, using the ABI
PRISM 7900HT System (Applied Biosystems, Inc.). Pre-
viously developed sequence detection reagents specific
for the human KIF20A gene (Applied Biosystems; ref
Hs00194882_m1) were used as described25 using the
2CT method.26 Statistical analyses were performed
using PRISM software (version 4; GraphPad Software,
Inc., San Jose, CA), and significance was determined
using the nonparametric Mann-Whitney U test. All values
reported are given as mean  SEM. Difference was con-
sidered significant at P  0.05.
Protein Extraction and Immunoblot Analysis
Proteinswere extracted inRIPAbuffer [50mmol/L TrisHCl (pH
7.5), 150 mmol/L NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxy-
cholate, 10 mmol/L -glycerophosphate, 1 mmol/L NaF, 0.1
mmol/L Na3VO4, 1 mmol/L dithiothreitol, and protease inhibi-
tors], followedby sonication (4°C, 9 30 seconds, 80%). After
electrophoresis and transfer, nitrocellulose membranes (Pro-
tran BA83; Whatman GmbH, Dassel, Germany) were incu-
bated with antibodies against MKlp2 (anti–rabkinesin-6,
1:1000, Echard et al8), Aurora B (1:250; AIM1, Cell Signaling
Technology, Inc., Beverly,MA), Importin-2 (1:200,D45; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), PCNA (1:5000,
PC10; Abcam Ltd., Cambridge, England), and Ser10-PH3 (1:
1000, H-0412), -tubulin (1:1000, DM1A), and actin (1:500,
AC15) (all three from Sigma-Aldrich Chimie SNC, St. Quentin
Fallavier, France), andeRF1 (1:1000,Chauvin et al27), followed
by peroxidase-coupled secondary antibodies (1:20,000; GE
Healthcare UK Ltd., Little Chalfont, Buckinghamshire, Eng-
land). Membranes were revealed using SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Perbio Science
France SA, Brebières, France).
Immunofluorescence Microscopy on Primary
Mouse Hepatocytes
Hepatocytes grown on coverslips were fixed with 2% para-
formaldehyde and permeabilized with 0.5% Triton X-100
before immunolabeling using antibodies against MKlp2 (1:
1000; Echard et al8), Aurora B (1:250, AIM1; Cell Signaling
Technology, Inc.), and GM130 (1:100; Becton Dickinson
France SAS, Grenoble, France), and Alexa-conjugated sec-
ondary antibodies (1:1000; Invitrogen BP, Cergy-Pontoise,
France). DNA was stained with 1 g/mL Hoechst 33258,
and the preparation was mounted in VectaShield medium
(Vector Laboratories, Ltd., Peterborough, England). Images
were obtained using an Olympus BX41 fluorescencemicro-
scope with a 40 objective (Olympus France SAS, Rungis,
France) from an RTKe Spot camera (Diagnostic Instru-
ments, Inc., Sterling Heights, MI) driven by Spot software,
and were processed using Adobe Photoshop CS2 software
(Adobe Systems, Inc., San Jose, CA).
Table 1. Clinical and Pathologic Characteristics of 125 Human
HCCs Analyzed for KIF20A mRNA*
Clinical or pathologic characteristic
HCC tumors
(n  125)
Age, mean (SD), years 60 (13)
Sex (M/F) 4:1
-Fetoprotein 100 64
Cirrhosis or hepatic adenoma 68
HBV infection 30
HCV infection 27
Alcoholism 34
Hemochromatosis 5
Diameter, mean (SD), cm 7.6 (4.5)
Edmondson grade III or IV 42
Microscopic vascular emboli 37
TP53 mutations 26
Chromosome instability (FAL  0.128) 46
*Unless otherwise indicated, values are given as percent.
FAL, fractional allelic loss; HBV, hepatitis B virus; HCV, hepatitis C virus.
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Immunohistochemistry on Human and Mouse
HCCs and Regenerating Mouse Liver
Four-micrometer FFPE sections were cut. The sections
were pretreated in a microwave oven at 750 W for 30
minutes in 10 mmol/L citrate buffer (pH 6.0). The sections
were pre-incubated with protein block (Novocastra Lab-
oratories, Ltd) for 5 minutes, and then incubated for 30
minutes with an anti–MKlp-2 antibody (rabbit polyclonal
anti-human MKlp2, Novus Biologicals, LLC, Littleton, CO,
1:100, and rabbit polyclonal anti-mouse MKlp2,8 1:500).
Post-primary block (Novolink Polymer Detection System;
Novocastra Laboratories, Ltd.) was applied to the spec-
imens for 20 minutes. Specimens were then washed with
PBS (pH 7.0) for 3 minutes, and incubated with Novolink
Polymer for 20 minutes. The Automate Staining System
(BioGenex Laboratories, Inc., San Ramon, CA) was used.
The color was developed using amino-ethyl-carbazole
(AEC peroxidase substrate kit; Vector Laboratories, Ltd.).
The sections were counterstained with hematoxylin.
Results
MKlp2 Is Accumulated in G2 and M Phases of
the Cell Cycle in Mitogen-Stimulated Primary
Mouse Hepatocytes
We first examined the timing of MKlp2 accumulation in
primary mouse hepatocytes cultured in vitro in the presence
of mitogens. Under these conditions, hepatocytes exit G0
and enter G1 on isolation, then enter the S phase at approx-
imately 20 hours (60% of the cells will progress through the
S phase within 24 hours), and demonstrate a maximal 10%
mitotic index at 50 hours after mitogen-stimulation.20 This
kinetics was confirmed by monitoring the accumulation of
two known cell cycle markers, proliferating cell nuclear an-
tigen (PCNA) and phospho-histone H3 (PH3). PCNA is ex-
pressed from late G1 to the M phase, whereas PH3 is
specific for mitotic cells.28,29 MKlp2 was not detectable in
purified nonstimulated hepatocytes (Figure 1A, time 0), as
was the case for PCNA and PH3, in agreement with the
observation that these cells are in early G1. MKlp2 began to
accumulate at 44 hours after mitogen stimulation, and re-
mained constant and high until 66 hours, whereas PCNA
accumulated from 19 hours with onset of the S phase, and
PH3 reached maximal levels at 52 hours, corresponding to
the peak of mitosis (Figure 1A). Thus, the timing of MKlp2
protein expression is intermediate between that of PCNA
and PH3, which suggests that MKlp2 is primarily accumu-
lated in the G2 and M phases.
To confirm this hypothesis, we monitored the intracel-
lular localization of MKlp2 during the cell cycle (Figure 1,
B and C; see also Supplemental Figure S1 at http://
ajp.amjpathol.org). MKlp2 was readily detected in mitotic
hepatocytes, with stage-specific re-localization of the
protein from the chromosomes and the mitotic spindle to
midzone microtubules, consistent with previous observa-
tions in several cell lines (see Supplemental Figure S1 at
http://ajp.amjpathol.org). However, in interphase, two pat-
terns of MKlp2 labeling were observed. The first was
punctuate and perinuclear, in good agreement with the
Figure 1. MKlp2 localizes to the Golgi apparatus throughout interphase and accumulates in the nucleus in the G2 phase in proliferating primary mouse
hepatocytes. A: Primary mouse hepatocytes were analyzed using Western blot at the indicated times after mitogen stimulation. Liver protein extracts were analyzed
in parallel using Western blot for MKlp2, PCNA, and PH3. eRF1 was used as a loading control. Results are from one of three independent experiments. B and D:
Mitogen-stimulated hepatocytes were fixed and labeled using antibodies directed against the indicated proteins. DNA was counterstained with Hoechst (blue).
Merge is shown on the right. Scale bar  5 m. B:MKlp2 (green) and the Golgi matrix protein GM130 (red). D:MKlp2 (green) and Aurora B kinase (red). Nuclear
Aurora B labeling is typical of G2 cells and is accompanied by MKlp2 labeling (asterisks). C:Histogram shows the percentage of nuclei immunolabeled for MKlp2.
All MKlp2-positive nuclei were also positive for the G2 marker Aurora B, and vice versa. Nuclei positive for only one of the two markers were not observed.
Between 685 and 890 nuclei were counted at each time. Results are the mean of three independent experiments.
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known association of the protein with the Golgi appara-
tus.8 To confirm the identity of the labeled structures, we
used antibodies to GM130, a cis-Golgi matrix protein.30
Figure 1B shows the co-localization of MKlp2 and GM130
on Golgi vesicles. Such labeling was observed in both
mononucleate and binucleate hepatocytes and could be
detected in most interphasic hepatocytes (Figure 1B,
upper panel; see also Supplemental Figure S1 at http://
ajp.amjpathol.org). The second pattern of MKlp2 labeling
was perinuclear and nuclear (Figure 1B, lower panel, and
1D; see also Supplemental Figure S1 at http://ajp.
amjpathol.org). The percentage of MKlp2-positive hepa-
tocyte nuclei depended, however, on the duration of mi-
togen stimulation, which suggests that it was dependent
on the cell cycle. Less than 1% of the nuclei were labeled
in hepatocytes stimulated for 28 hours, whereas these
cells exhibited Golgi labeling (Figure 1C). Of note, MKlp2
remained undetectable by immunoblotting in these sam-
ples (Figure 1A). After 44 hours of mitogen stimulation, the
percentage of cells exhibiting nuclear labeling increased to
about 8%, and eventually decreased at 52 hours. MKlp2
was readily detectable in these samples by immunoblotting.
Therefore, detection of nuclear MKlp2 labeling coincides
with the period of MKlp2 accumulation as detected by im-
munoblotting. To determine whether this occurs during the
G2 phase of the cell cycle, we used Aurora B as a G2-
specific nuclear marker. Aurora B is one of the major ki-
nases that control progression through mitosis.2 In a wide
variety of cell types, nuclear accumulation of Aurora B oc-
curs in G2 before mitosis. Aurora B then persists throughout
mitosis, and is degraded on mitotic exit. Immunofluores-
cence data (Figure 1D) demonstrated that Aurora B and
MKlp2 are co-expressed in the nucleus of mitogen-stimu-
lated hepatocytes. We observed that all MKlp2-positive nu-
clei were also positive for Aurora B, and vice versa, through-
out the culture period, with a maximum 44 hours after
mitogen stimulation (Figure 1C). These results demonstrate
that MKlp2 is accumulated during G2 in the nucleus of
mitogen-stimulated hepatocytes.
MKlp2 Is Strongly Accumulated During Mouse
Liver Regeneration
Liver regeneration after partial hepatectomy has been
widely used to study the hepatocyte cell cycle because it
provides a physiologic setting of normal cell division.
After partial hepatectomy in the mouse, hepatocytes un-
dergo a first round of synchronized cell division, with
peak DNA synthesis occurring at 36 hours after partial
hepatectomy and a maximal mitotic index at 48 hours
after partial hepatectomy.31 A second wave of hepato-
cyte cell division occurs during the next 48 hours but is
less synchronous and overlaps with division of other liver
cell types. To determine the expression pattern of MKlp2
during liver regeneration, livers were collected between
32 and 96 hours after partial hepatectomy, representing
the interval of two hepatocyte cell division cycles. To
monitor the hepatocyte cell cycle, liver sections were
analyzed for Ki-67 immunolabeling of hepatocyte nuclei
(Figure 2A). Ki-67 is absent in quiescent cells but is
accumulated in late G1 and is present in all subsequent
cell cycle phases. In the present study, we observed that
the number of Ki-67–positive hepatocyte nuclei in-
creased from 36 to 48 hours after partial hepatectomy,
then gradually decreased as hepatocytes progressively
ceased to proliferate, and no Ki-67–positive nuclei were
detected in quiescent liver (time 0). Therefore, hepato-
cytes reached late G1 at 36 hours after partial hepatec-
tomy and afterward. As expected, neither PCNA nor PH3
was detectable in quiescent liver or in regenerating liver
until 36 hours after partial hepatectomy. Levels of PCNA
increased from 40 hours, to reach a maximum at 48 hours
after partial hepatectomy, and remained elevated. This
indicated that the hepatocyte S phase started at approx-
imately 40 hours after partial hepatectomy. Maximal lev-
els of PH3 were observed primarily at 48 and 96 hours
after partial hepatectomy, representing the two succes-
sive waves of hepatocyte mitosis. The timing of MKlp2
Figure 2. MKlp2 strongly accumulates during mouse liver regeneration and
hepatocarcinogenesis. A: Upper panel, Histogram shows the time course of
hepatocyte proliferation during liver regeneration assessed by Ki-67 immu-
nolabeling. Positive Ki-67 hepatocyte nuclei were counted in 10 consecutive
fields from each liver section at the indicated time after partial hepatectomy
and are expressed as mean  SEM. Lower panel, Liver protein extracts were
analyzed in parallel using Western blot for MKlp2, PCNA, and PH3. eRF1 was
used as a loading control. B: Mouse liver protein extracts were analyzed in
parallel using Western blot for MKlp2, Aurora B, cyclin B, and PCNA. -
Tubulin was used as a loading control. Control, 2- and 6-month-old non-
transgenic males; ASV, male transgenic mice with nuclear atypias in the liver
(2 months old) and HCC (6 months old).
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protein expression was intermediate between that of
PCNA and PH3 (Figure 2A). MKlp2 expression was un-
detectable in quiescent liver (time 0) but dramatically
increased at 44 hours, after the increase in PCNA, and
reached a maximum at 48 hours after partial hepatec-
tomy, coincident with maximal accumulation of PH3.
MKlp2 protein levels then decreased at 72 hours, and
increased again at 96 hours after partial hepatectomy,
coincident with the second wave of hepatocyte mitosis.
Accumulation of MKlp2 in the hepatocyte population of
cells in the regenerating liver was confirmed by in situ
analysis of fixed liver samples. At 48 hours after partial
hepatectomy, approximately 40% of the nuclei were
strongly positive for MKlp2 labeling, whereas no labeling
was observed in quiescent liver (Figure 3A). Mitotic hepa-
tocytes with labeled chromosomes were also observed at
48 and 96 hours after partial hepatectomy. These obser-
vations are consistent with our finding that MKlp2 mostly
accumulates in the G2 phase, and mitosis in mitogen-
stimulated hepatocytes proliferating in vitro.
MKlp2 Is Overexpressed During Mouse Liver
Transformation
ASV transgenic mice provide a well-characterized model
of large T antigen–induced hepatocarcinogenesis. Male
transgenic mice develop hepatocellular atypias and ab-
normal levels of mitosis in the liver at age 2 months,
followed by the emergence of diffuse hepatocellular car-
cinoma in all animals at age 6 months. The presence of
proliferating cells in these tissues is characterized by
overexpression of the cell cycle proteins cyclin B and
PCNA (Figure 2B). We observed that MKlp2 is overex-
pressed in both preneoplastic livers at age 2 months and
hepatocarcinomas in 6-month-old male transgenic mice
(Figure 2B), whereas it remains undetectable in control liver
from nontransgenic males (Figure 2B) and female litter-
mates (not shown). Similarly, the mitotic kinase Aurora B
was also increased. Accumulation of MKlp2 in transformed
liver was finally confirmed by in situ analysis of fixed liver
samples. Approximately 10% of the nuclei were strongly
positive for MKlp2 labeling in hepatocarcinoma sections
from transgenic mice, whereas no labeling was observed in
nontransgenic normal liver (Figure 3B).
MKlp2 Is Overexpressed in Human Hepatoma
Cell Lines
We first analyzed MKlp2 expression in a panel of human
hepatoma cell lines and in normal human hepatocytes in
primary culture (Figure 4A). It was observed that MKlp2 is
undetectable in normal primary hepatocytes but is ex-
pressed at intermediate levels in PLC/PRF/5 and HepG2
to high levels in HuH6, HuH7 and Hep3B cell lines. Mi-
croscopic analysis demonstrated that the intracellular lo-
calization of MKlp2 followed the pattern observed in pri-
mary mouse hepatocytes (exemplified for the HuH6 cell
line in Supplemental Figure S2, available at http://ajp.
amjpathol.org). We then used RNA interference to inves-
tigate the function of MKlp2 in HuH6 and HuH7 cells. The
HuH7 cell line is mutated in the TP53 gene, and cells tend
to become spontaneously polyploid. Knockdown of
MKlp2 was efficient in both cell lines (Figure 4B). This
was accompanied in HuH6 cells by the appearance of
polyploid cells, with a slight increase in the percentage of
cells with 4n DNA content, from 2.2% to 3.8%. A dra-
matic effect was obtained in HuH7 cells, passing from
26.3% to 73.2% of cells with 4n DNA content on MKlp2
knockdown. In these two cell lines, modeling of the cell
cycle predicted the presence of cycling tetraploid cells at
higher frequency after MKlp2 knockdown. Microscopic
analysis indicated that cells down-regulated for MKlp2
exhibited abnormal mitoses, with mispositioned chromo-
somes in metaphase and reduced furrow ingression in
telophase and cytokinesis (see Supplemental Figure S2
at at http://ajp.amjpathol.org). Therefore, MKlp2 is re-
quired to prevent polyploidization and to promote cytoki-
nesis in human hepatoma cells. However, no obvious
increase in the sub-G1 population and no apoptosis were
detected after MKlp2 knockdown (see Supplemental Fig-
ure S3A at http://ajp.amjpathol.org).
To investigate long-term effects of MKlp2 knockdown
in hepatoma cells, we selected for stable expression of
MKlp2 shRNA in HuH6 cells. The number of macro col-
onies (50 cells) formed after 14 days of selection was
severely reduced (Figure 4C). In addition, we observed
Figure 3. Mklp2 immunolabeling in regenerating mouse liver and in murine
and human HCC. Tissue sections from regenerating liver and HCC were
labeled using anti-Mklp2 antibodies, and were counterstained with hema-
toxylin. Representative images are shown. A: Regenerating mouse liver at the
indicated time after hepatectomy. Typical nuclear hepatocyte labeling is
observed at 48 hours after hepatectomy. Hepatocytes in mitosis exhibit
strongly labeled chromosomes (best observed at 96 hours after hepatec-
tomy). No labeling is detected in quiescent liver (time 0). Scale bar  50 m.
B: Mouse and human liver tumors. Typical nuclear hepatocyte labeling is
observed in liver tumors, representing approximately 10% and 40% of the
nuclei in mouse and human tumors, respectively, whereas this labeling was
absent in control liver. Scale bar  100 m.
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the persistence of binucleate cells and cells with severe
nuclear abnormalities (enlarged multilobulated nuclei
and micronuclei) consistent with a cytokinesis defect.
They were observed as singlets and in microcolonies of
20 cells (see Supplemental Figure S3, B–E, at http://
ajp.amjpathol.org). This result indicated that down-regu-
lation of MKlp2 is incompatible with sustained cell prolif-
eration.
MKlp2 Is Overexpressed in Specimens of
Human HCC
To determine whether MKlp2 overexpression is a general
feature of liver oncogenic transformation, we evaluated
the levels of MKlp2 in a small series of human HCC
specimens in comparison with nontumoral adjacent liver
tissue. MKlp2 was largely overexpressed in four tumor
samples (from patients 1, 2, and 3) compared with the
adjacent tissue, independent of liver status (healthy or
cirrhotic liver) (Figure 5). In one patient (patient 4), MKlp2
was similarly expressed in both tumor and nontumor
samples. MKlp2 was barely detectable in the last spec-
imen analyzed (patient 5). There was good but not abso-
lute correlation between MKlp2 overexpression and the
presence of proliferating cells in the samples, as judged
from accumulation of the cell cycle proteins cyclin B and
PCNA. MKlp2 mobility at SDS-PAGE was altered in four
tumor samples (samples 1, 3T2, 4, and 5). In patient 3,
this alteration was observed in one tumor (T2) but not the
other (T1). These observations suggest that MKlp2 could
be the subject of post-translational modifications specific
to a subset of HCCs.
Overexpression of the mitotic kinase Aurora B in tu-
moral samples compared with nontumoral samples was
observed in only two patients (patients 2 and 3). Expres-
sion without accumulation in the tumor was observed in
one patient (patient 1). Aurora B was barely detectable in
samples from two patients (patients 4 and 5). Accumu-
Figure 4. Hepatoma cells with reduced MKlp2 levels demonstrate polyp-
loidization. A and B: Western blot analysis of normal human primary hepa-
tocytes and the indicated hepatoma cell lines. A: Detection of MKlp2 and
Aurora B. Actin was used as a loading control. B: HuH6 and HuH7 hepatoma
cells transfected for 36 hours with pSuper plasmids expressing control (Ctr)
or MKlp2 sh-RNAs (Mklp2) were analyzed for MKlp2, Aurora B, and impor-
tin- (loading control). Cells were analyzed in parallel using flow cytometry.
Values represent percentage of cells with the indicated DNA contents, either
as separate classes (2n, 4n, and 4n DNA contents) or as two overlapping
cell cycles (diploid and tetraploid). C: Colony formation assay in HuH6
hepatoma cells stably expressing MKlp2 (black) and control (gray) shRNA
and neo expressing vector. Quantification of the number of colonies per
25-cm2 flask demonstrates a significant reduction in the number of macro-
colonies (n 50 cells per colony) and persistence of single cells and micro-
colonies (n 20 cells per colony) on down-regulation of MKlp2. The exper-
iment was performed in triplicate, and the two-tailed Student’s t-test was used
to evaluate statistical significance (*P  0.05; **P  0.005; ***P  0.0005).
Figure 5. MKlp2 strongly accumulates during human hepatocarcinogenesis.
Tumoral (T) and nontumoral (NT) adjacent liver tissue from five patients with
HCC were analyzed using Western blot for MKlp2, Aurora B, cyclin B, and
PCNA. Equivalent protein loading was assessed with red Ponceau staining.
Patients 1, 3, and 4 were without fibrosis. Patients 2 and 5 had hepatitis C
virus infection and cirrhosis. Two separate tumors (T1 and T2) were obtained
from the same patient.
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lation of MKlp2 in human HCCs was confirmed using
immunohistochemistry. A strong nuclear labeling for
MKlp2 in human HCC tissue sections was observed in
approximately 40% of the cells, and the adjacent nontu-
moral tissue was unlabeled (Figure 3B). Altogether, these
observations demonstrate that accumulation of nuclear
MKlp2 is a prominent feature of tumoral liver cells.
MKlp2 Encoding KIF20A mRNA Is Increased in
a Wide Range of Human HCCs, with the
Highest Levels Linked to Chromosome
Instability
To determine whether overexpression of MKlp2 is defi-
nitely linked to human hepatocarcinogenesis, we used
quantitative RT-PCR to measure the level of KIF20A
mRNA in a series of 125 tumors that have been already
classified into six subgroups associated with clinical and
genetic characteristics.24 KIF20A mRNA was increased
8- to 40-fold in all HCC subgroups compared with normal
liver tissues (Figure 6A). The highest levels of expression
were observed in subgroups G1, G2, and G3, which are
all significantly associated with chromosome instability
and increased cell proliferation.
Subgroup G3 demonstrated the highest value, with a
40-fold increase in KIF20A mRNA. This subgroup is de-
fined by up-regulation of several checkpoint proteins in-
volved in cell-cycle control, TP53 mutation, and absence
of HBV infection. We then analyzed the association be-
tween KIF20A mRNA accumulation and clinical factors
and genetic alterations. KIF20A mRNA levels were sig-
nificantly higher in HCCs harboring mutations in TP53
(subgroups G2 and G3), infected with hepatitis B virus
(subgroups G1 and G2), or associated with high -feto-
protein levels (Figure 6B). Significantly higher KIF20A
mRNA levels were also observed in poorly differentiated
and undifferentiated tumors (Edmondson grades III and
IV, respectively) compared with well-differentiated and
moderately differentiated tumors (Edmondson grades I
and II, respectively). However, KIF20A mRNA levels
were not significantly linked to alcohol, cirrhosis, hep-
atitis C virus infection, or -catenin mutations (not
shown). Therefore, high levels of KIF20A mRNA were
significantly linked to the most proliferative and undif-
ferentiated HCCs.
Discussion
HCC is a common fatal malignant tumor that is charac-
terized by a high incidence of recurrence, development
of resistance to chemotherapy, and low sensitivity to ra-
diation therapy. Identification of novel biomarkers for pre-
dictive medicine is required to better classify HCCs ac-
cording to the probability of recurrence after chemical
therapy or surgical resection. In the present study, we
demonstrate that the mitotic kinesin MKlp2 is deregulated
during human and mouse hepatocarcinogenesis. MKlp2
encoding KIF20A mRNA is significantly overexpressed in
human HCCs, with the highest levels linked to chromo-
some instability. At the protein level, MKlp2 accumulation
was also observed in human hepatoma cell lines and in
human HCC specimens irrespective of whether the un-
derlying liver was cirrhotic or was affected with periportal
fibrosis (data not shown). We observed increased MKlp2
protein expression in HCCs from a murine model of hepa-
tocarcinogenesis, and in this model, MKlp2 overexpres-
sion was detected at preneoplastic stages. In addition,
we demonstrated that MKlp2 is cell cycle–regulated in
normal hepatocytes, being accumulated in the G2 phase
and in mitosis in primary hepatocytes. In contrast, MKlp2
is barely detectable in quiescent liver and hepatocytes.
RNA interference assays demonstrated that MKlp2 was
functional in human hepatoma cells and was required to
prevent polyploidization. MKlp2 knockdown did not in-
duce apoptosis, but inhibited cell proliferation on stable
expression.
Figure 6. MKlp2 encoding KIF20A mRNA is dramatically increased in hu-
man HCCs and is linked to tumor aggressiveness. KIF20A gene expression
was quantified using RT-PCR. Results were first normalized to control ribo-
somal 18S in all samples. A: Results in HCC samples are expressed as a ratio
relative to the mean expression level in six control liver samples (Ctr). Bars
show the values as mean  SEM. Significance determined using the non-
parametric Mann-Whitney U test was P  0.0001 (difference was considered
significant at P  0.05). B: Monoparametric analysis of KIF20A mRNA ex-
pression in HCCs with chromosome instability [FAL, frequency of allelic loss
(white, P  0.0001), TP53 gene mutation (gray, P  0.0001), Edmondson
histologic grade (black, P  0.0009), serum -fetoprotein concentration
(AFP, hatched, P  0.001), and hepatitis B virus infection (dotted, P  0.001).
Bars show the values as mean  SEM. *P  0.05.
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Our observations in mouse primary hepatocytes dem-
onstrate that MKlp2 nuclear accumulation occurs in G2
coincident with the mitotic kinase Aurora B. The gene
encoding Aurora B was observed to be significantly over-
expressed in a recent genome-wide microarray analysis
of 107 human HCCs, and was the most significant pre-
dictor of aggressive recurrence.32 In that study, genes
encoding several cytokinesis- and mitotic spindle–asso-
ciated proteins including KIF20A were observed to be
up-regulated in HCCs with an aggressive pattern of re-
currence. Our observation that MKlp2 is overexpressed
at the mRNA level in human HCCs is in good agreement
with that study and indicates that MKlp2 overexpression
resulted from either enhanced gene transcription or
mRNA stabilization during liver transformation.
Several lines of evidence indicate that the two genes
encoding MKlp2 and Aurora B are co-regulated, al-
though they are located on different chromosomes. The
promoter regions of both genes share common regula-
tory sequences such as the cell cycle–dependent ele-
ment and cell cycle homology region, which are able to
bind specific E2F/DP complexes mediating both tran-
scriptional repression in G0 through pRb and activation in
S/G2.6,33 Liver-specific inactivation of pRb in the mouse,
which mimics the situation observed at high frequency in
human HCCs, results in deregulation of E2F target genes
and aberrant ploidy.16,34 In the present study, we dem-
onstrate that alteration of the pRb and p53 tumor-sup-
pressor protein mediated by large T antigen in the mouse
liver is sufficient to up-regulate both MKlp2 and Aurora B.
This up-regulation is observed in preneoplastic livers and
persists in HCCs, which suggests a role for MKlp2 at both
early and later stages of liver carcinogenesis. In good
agreement with these observations in the mouse, in hu-
mans, high levels of MKlp2 encoding mRNA are ob-
served in HCCs with mutated TP53. Studies of chromatin
immunoprecipitation have demonstrated that the fork-
head transcription factor FoxM1 is an essential transcrip-
tional regulator of both MKlp2 and Aurora B.35 Elevated
expression of FoxM1 has been demonstrated in human
HCCs, and, conversely, FoxM1/ mice exhibit defects in
tissues that normally become polyploid such as liver and
heart, with an up to 50-fold increase in DNA content.36
Inhibition of FoxM1 by a cell penetrating ARF peptide was
recently demonstrated to induce apoptosis in human
HCC cell lines and mouse models.37 Therefore, deregu-
lation of the transcriptional circuitry depending on both
pRb/E2F and Fox M1 leads to up-regulation of at least the
two target genes Aurora B and KIF20A, which may be
sufficient to impair mitosis and cytokinesis, leading to
aberrant ploidy and genomic instability.
Transcriptome classification of human HCCs demon-
strated that groups associated with a high rate of chro-
mosomal instability were enriched with cell cycle, prolif-
eration, and DNA metabolism genes.24 In the same
series, we observed the highest levels of KIF20A mRNA
in subgroup G3, which includes tumors specified by mu-
tation of TP53, a global overexpression of cell cycle
genes, and inactivation of the pRb pathway through
CDKN2A promoter methylation. This result is in agree-
ment with KIF20A belonging to the cell cycle gene family
and being a target of E2F transcription factor.
In conclusion, our observation that MKlp2 accumulates
in normal proliferating hepatocytes and liver cancer cells
suggests that MKlp2 contributes to both normal and ma-
lignant hepatocyte proliferation. Furthermore, our data
indicate that MKlp2 should be considered a new predic-
tor candidate for HCC. Specific and stable inhibition of
MKlp2 (now feasible using the new selective inhibitor
paprotrain38) seems to be a new antiproliferative strategy
in the treatment of liver cancer.
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